STADA Arzneimittel AG
Profile managed by Bizz IdDescription
Products
7 productsBiosimilar. Autoimmune diseases. Partner: Alvotech (Europe).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar. Oncology (breast, cervical, colorectal, NSCLC, ovarian, renal cell cancers). Partner: mAbxience; launched in Germany and the Netherlands.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar. Symptomatic anemia associated with chronic renal failure. Launched in 2008.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar. Cancer patients with neutropenia. In selected markets.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar. Ophthalmology: wet age-related macular degeneration and diabetic macular oedema. Partner: Xbrane.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Movymia. Biosimilar. Osteoporosis. In-licensed from Richter-Helm-BioTec; launched in 24 countries.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Code AVT04. Biosimilar to Stelara. Partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21